

Supplementary Table 1. Home medications of the study population at baseline, stratified by vital status at discharge*

Variable	Total	Died	Discharged alive	p-value
	N (%) (n = 2054)	N (%) (n = 439)	N (%) (n = 1553)	
NSAID	55 (2.7)	16 (3.6)	37 (2.4)	0.177
Amiodarone	17 (0.8)	7 (1.6)	9 (0.6)	0.061
Oral anticoagulant	130 (6.3)	33 (7.5)	93 (6.0)	0.266
Betablocker	364 (17.7)	87 (19.8)	260 (16.7)	0.135
Calcium channel blocker	250 (12.2)	70 (15.9)	174 (11.2)	0.010
Inhaled corticosteroids	73 (3.6)	14 (3.2)	54 (3.5)	0.882
Oral corticosteroids	51 (2.5)	9 (2.1)	40 (2.6)	0.604
Digitalis	8 (0.4)	2 (0.5)	6 (0.4)	0.691
Loop diuretic	158 (7.7)	46 (10.5)	102 (6.6)	0.007
Potassium sparing diuretic	68 (3.3)	22 (5.0)	40 (2.6)	0.013
Thiazide diuretic	389 (14.1)	74 (16.9)	209 (13.5)	0.075
Statin	345 (16.8)	93 (21.8)	245 (15.5)	0.009
Hypoglycemic drug	407 (19.8)	90 (20.5)	307 (19.8)	0.735
Immunosuppressant	39 (1.9)	6 (1.4)	32 (2.1)	0.432
ACE inhibitor or ARB blocker	735 (35.8)	185 (42.1)	526 (33.9)	0.002
Insulin	177 (8.6)	59 (13.4)	109 (7.0)	<0.001

* From the 2054 patients included in the analysis, 62 patients were transferred to another hospital. As final survival status was unknown, they were not included in the stratified analysis.

Values in numbers (percentage).

ACE: angiotensin-converting enzyme, ABR: angiotensin II receptor, NSAID: nonsteroidal anti-inflammatory drug

Supplementary Table 2. In-hospital mortality and length of stay (days) by 10-year age interval, sex and survival status (n=1974)*

Age	Died			Discharged alive		
	Male N/N (%)	Female N/N (%)	Length of stay Median (IQR)	Male N/N (%)	Female N/N (%)	Length of stay Median (IQR)
0-9	1/6 (16.7)	0/5 (0)	-	5/6 (83.3)	5/5 (100)	5.5 (3-9)
10-19	-	1/6 (16.7)	-	-	5/6 (83.3)	6 (3.5-19)
20-29	4/42 (9.5)	3/43 (7.0)	6 (5-11)	38/42 (90.5)	40/43 (93.0)	5.5 (3-9)
30-39	10/93 (10.8)	1/87 (1.1)	10 (5-18)	83/93 (89.2)	86/87 (98.9)	6 (3-10)
40-49	29/219 (13.2)	11/142 (7.7)	11.5 (7-18)	190/219 (86.8)	131/142 (92.3)	6 (4-9)
50-59	40/220 (18.2)	24/179 (13.4)	10 (6-21)	180/220 (81.8)	155/179 (86.6)	7 (4-12)
60-69	59/219 (26.9)	38/181 (21.0)	14 (8-20)	160/219 (73.1)	143/181 (79.0)	8 (5-14)
70-79	45/139 (32.4)	57/169 (33.7)	12 (6-19)	94/139 (67.6)	112/169 (66.3)	9 (5-14)
80-89	39/84 (46.4)	46/97 (47.4)	12 (7-16)	45/84 (53.6)	51/97 (52.6)	9 (5-14)
≥ 90	9/13 (69.2)	18/29 (62.1)	7 (3-11)	4/13 (30.8)	11/29 (37.9)	12 (4-21)

* This table included patients with complete follow-up (discharged alive or death), except 18 patients had missing values for birth date (8 men and 10 women)

Values in numbers (percentage) or medians (interquartile range, IQR).

Supplementary Table 3. Additional laboratory parameters, imaging and electrocardiographic parameters of the study population at admission*

Variable	Total N	Died	Discharged alive	p-value
Albumin (g/dL)	(n = 481) 3.20 (2.80 – 3.60)	(n = 157) 3.00 (2.60-3.30)	(n = 308) 3.40 (3.00-3.70)	<0.001
Total bilirubin (mg/dL)	(n = 959) 0.41 (0.30 – 0.62)	(n = 257) 0.50 (0.30 - 0.70)	(n = 671) 0.40 (0.30 - 0.60)	<0.001
BNP (pg/ml)	(n = 39) 43.00 (5.50 – 455.00)	(n = 9) 237.70 (24.50 - 4295.5)	(n = 28) 22.75 (5.00-76.0)	0.037
NT-pro-BNP (pg/mL)	(n = 196) 127.50 (46.25 – 434.75)	(n = 37) 729.0 (203.98 - 2100.50)	(n = 147) 84.83 (39.00 - 259.00)	<0.001
Creatine phosphokinase (CPK– U/L)	(n = 484) 95.06 (52.25 – 202.25)	(n = 127) 143.38 (69.00 - 318.00)	(n = 344) 87.00 (51.00 - 117.25)	<0.001
D-dimer > URL**	(n = 1054) 810 (76.9)	(n = 203) 180 (88.7)	(n = 821) 605 (73.7)	<0.001
Ferritin (ng/mL)	(n = 337) 577.60 (286.65 - 1242.7)	(n = 64) 945.83 (385.40 - 1976.50)	(n = 268) 550.15 (275.17 - 1186.20)	0.011
Fibrinogen (g/L)	(n = 97) 486.00 (366.50 – 638.00)	(n = 27) 568.00 (379.00-689.00)*	(n = 66) 464.50 (362.25-611.00)	0.312
Lactate dehydrogenase (U/L)	(n = 951) 354.00 (264.00 – 498.00)	(n = 200) 502.00 (368.00 - 706.50)	(n = 733) 327.00 (254.00 -445.00)	<0.001
AST (U/L)	(n = 1159) 42.00 (29.41 – 61.00)	(n = 270) 49.00 (34.00 - 74.75)	(n = 849) 40.00 (29.00 - 58.07)	<0.001
	(n = 1158)	(n = 268)	(n = 848)	

ALT (U/L)	34.00 (22.00– 57.95)	34.0 (21.0 - 53.7)	35.2 (22.1 - 59.0)	0.203
	(n = 784)	(n = 182)	(n = 573)	
Troponin > URL**	180 (23.0)	81 (44.5)	85 (14.8)	<0.001
Chest radiography	(n=1219)	(n = 274)	(n = 897)	
Atelectasis	29 (2.4)	3 (1.1)	25 (2.8)	0.119
Cavitation	4 (0.3)	1 (0.4)	3 (0.3)	1.000
Consolidation	209 (17.1)	76 (27.7)	130 (14.5)	<0.001
Pleural thickening	13 (1.1)	6 (2.2)	5 (0.6)	0.025
Diffuse interstitial thickening	507 (41.6)	134 (48.9)	355 (39.6)	0.006
Focal interstitial thickening	142 (11.6)	30 (10.9)	105 (11.7)	0.829
Bilateral ground glass opacity	213 (17.5)	60 (21.9)	145 (16.2)	0.036
Unilateral ground glass opacity	44 (3.6)	12 (4.4)	31 (3.5)	0.466
Central ground glass opacity	22 (1.8)	9 (3.3)	13 (1.4)	0.071
Peripheral ground glass opacity	80 (6.6)	19 (6.9)	59 (6.6)	0.890
Pneumothorax	7 (0.6)	4 (1.5)	1 (0.1)	0.012
None	264 (21.7)	35 (12.8)	219 (24.4)	<0.001
Chest CT	(n=913)	(n = 156)	(n = 738)	
Atelectasis	100 (11.0)	15 (9.6)	82 (11.1)	0.672
Cavitation	7 (0.8)	0 (0.0)	7 (0.9)	0.612
Consolidation	260 (28.5)	59 (37.8)	198 (26.8)	0.008
Pleural effusion	76 (8.3)	26 (16.7)	46 (6.2)	<0.001
Vascular thickening	49 (5.4)	12 (7.7)	36 (4.9)	0.170
Halo sign	6 (0.7)	1 (0.6)	5 (0.7)	1.000
One-sided ground glass opacity	43 (4.7)	11 (7.1)	30 (4.1)	0.137
Bilateral ground glass opacity	684 (74.9)	111 (71.2)	562 (76.2)	0.186

Central ground glass opacity	67 (7.3)	11 (7.1)	52 (7.0)	1.000
Peripheral ground glass opacity	392 (42.9)	49 (31.4)	336 (45.5)	0.001
Crazy-paving pattern	96 (10.5)	16 (10.3)	79 (10.7)	1.000
Inverted halo sign	14 (1.5)	2 (1.3)	12 (1.6)	1.000
None	44 (4.8)	6 (3.8)	35 (4.7)	0.833
Electrocardiogram	(n = 473)	(n = 335)	(n = 119)	
Sinus rhythm	374 (79.1)	85 (71.4)	275 (82.1)	0.018
Atrial fibrillation / flutter	25 (5.3)	10 (8.4)	12 (3.6)	0.046
Pacemaker	5 (1.1)	2 (1.7)	2 (0.6)	0.282
Multifocal atrial rhythm	3 (0.6)	2 (1.7)	1 (0.3)	0.169
SV tachycardia	3(0.6)	2 (1.7)	1 (0.3)	0.169
Primary repolarization abnormalities	59 (2.9)	19 (16.0)	37 (11.0)	0.193
Right bundle branch block	22 (1.1)	6 (5.0)	16 (4.8)	1.000
Left bundle branch block	16 (0.8)	6 (5.0)	9 (2.7)	0.236
First degree atrioventricular block	7 (0.3)	4 (3.4)	2 (0.6)	0.043
Second degree atrioventricular block	1 (0.04)	0 (0.0)	1 (0.3)	1.000
Third degree atrioventricular block	3 (0.04)	3 (2.5)	0 (0.0)	0.018
Left anterior hemiblock	18 (0.9)	12 (10.1)	6 (1.8)	<0.001
Pathological Q waves	5 (0.2)	0 (0.0)	5 (1.5)	0.333

* From the 2054 patients included in the analysis, 62 patients were transferred to another hospital. As the final survival status was unknown, they were not included in the stratified analysis. Total number of valid cases for each analysis is presented.

** As the assays for troponin and D-dimer varied among different centers, for this parameter the proportion of patients with values above the upper reference limit (URL) was assessed.

Values in median (interquartile range) and numbers (percentage)

